Vasomotor Symptom Relief With Hormone Therapy
Placeholder: HRT is the most effective treatment for hot flashes.
- ~75%: Hot flash reduction (placeholder figure)
- Improved: Sleep quality (placeholder figure)
- High: Genitourinary relief (placeholder figure)
- 2–4 wks: Onset of effect (placeholder figure)
Mechanism of symptomatic benefit
Placeholder: estrogen stabilizes thermoregulatory center function.
The Timing Hypothesis — Cardiovascular Risk Window
Placeholder: CV risk-benefit shifts with years since menopause onset.
- Favorable: Window <10 yrs (placeholder figure)
- Cautionary: Window >10 yrs (placeholder figure)
- Transdermal lower: Route effect (placeholder figure)
- Age-stratified: WHI reanalysis (placeholder figure)
Timing hypothesis mechanism
Placeholder: early initiation favors vascular health outcomes.
Breast Cancer Risk Considerations by Regimen
Placeholder: combined therapy carries different risk than estrogen-alone.
- Lower risk: Estrogen-alone (placeholder figure)
- Modest increase: Combined EPT (placeholder figure)
- Risk rises w/ time: Duration effect (placeholder figure)
- Declines after stop: Risk reversibility (placeholder figure)
Regimen-dependent risk profile
Placeholder: progestin component modifies breast cancer risk.
Bone Mineral Density Protection and Fracture Reduction
Placeholder: HRT preserves bone density and lowers fracture risk.
- Reduced: Hip fracture (placeholder figure)
- Reduced: Vertebral fracture (placeholder figure)
- Preserved: BMD change (placeholder figure)
- While on therapy: Effect duration (placeholder figure)
Skeletal protective mechanism
Placeholder: estrogen suppresses osteoclast-mediated bone resorption.
Shared Decision-Making for Individualized HRT Use
Placeholder: decisions weigh symptoms, age, and personal risk factors.
- Age at start: Key factor (placeholder figure)
- Baseline risk: Key factor (placeholder figure)
- Symptom severity: Key factor (placeholder figure)
- Annual: Review interval (placeholder figure)
Balancing individual risk and benefit
Placeholder: shared decision-making integrates all risk-benefit inputs.
Placeholder: individualized risk-benefit assessment guides HRT decisions.